Vertical/Trigen and Osmotica to combine

USA-based companies Vertical/Trigen Holdings and Osmotica Holdings Corp have entered into a definitive agreement to combine, creating a world-class, fully-integrated specialty pharmaceutical and generics company.

Vertical/Trigen is a portfolio company of Avista Capital Partners, a private equity firm. The combined company will be jointly owned by the current owners of Vertical/Trigen and Osmotica. Financial terms of the transaction were not disclosed.

The combination brings together two highly complementary businesses with demonstrated expertise in developing commercially successful pharmaceutical products. Utilizing Vertical/Trigen's strong front-end commercialization capabilities, the new company will be well-positioned to leverage Osmotica's portfolio of attractive approved products, differentiated formulation technology, proven R&D function, and high-quality manufacturing facility to effectively compete in the pharmaceuticals sector. The new entity, which will retain the Osmotica name, will continue to offer Vertical/Trigen's full portfolio of branded and generic products, as well as Osmotica's successful extended-release formulations upon achieving the required regulatory approval.